SEC Form 4 · accession 0001123292-16-003026
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Diane Myers
Director
Period of report
Dec 1, 2016
Accepted (ET)
Dec 5, 2016 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 1, 2016 | M | 2,500 | — | A | 4,060 | D | |
| Common Stock | Dec 1, 2016 | F | 777 | $6.48 | D | 3,283 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 1, 2016, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 2,500 performance-based restricted stock units, which were converted into 2,500 shares of common stock on a one-for-one basis.